A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma
- PMID: 20482867
- PMCID: PMC2882358
- DOI: 10.1186/1471-2490-10-9
A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma
Abstract
Background: Osteoporosis could be associated with the hormone therapy for metastatic prostate carcinoma (PCa) and with PCa per se. The objective of this review is to determine the incidence of bone loss and osteoporosis in patients with PCa who are or are not treated with hormone therapy (ADT).
Methods: The Medline, Embase, Cancerlit, and American Society of Clinical Oncology Abstract databases were searched for published studies on prostate cancer and bone metabolism. The outcomes assessed were: fracture, osteoporosis and osteopenia.
Results: Thirty-two articles (116,911 participants) were included in the meta-analysis. PCa patients under ADT had a higher risk of osteoporosis (RR, 1.30; p < 0.00001) and a higher risk of fractures (RR, 1.17; p < 0.00001) as compared to patients not under ADT. The total bone mineral density was lower in patients under ADT when compared with patients not under ADT (p = 0.031) but it was similar to bone mineral density found in healthy controls (p = 0.895). The time of androgen deprivation therapy correlated negatively with lumbar spine and total hip bone mineral density (Spearman's rho = -0.490 and -0.773; p = 0.028 and 0.001, respectively) and with total hip t score (Spearman's rho = -0.900; p = 0.037).
Conclusion: We found consistent evidence that the use of androgen deprivation therapy in patients with PCa reduces bone mineral density, increasing the risk of fractures in these patients.
Figures





Similar articles
-
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.Cochrane Database Syst Rev. 2020 Dec 3;12(12):CD013020. doi: 10.1002/14651858.CD013020.pub2. Cochrane Database Syst Rev. 2020. PMID: 33270906 Free PMC article.
-
Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2012 Mar;15(1):36-44. doi: 10.1038/pcan.2011.4. Epub 2011 Sep 6. Prostate Cancer Prostatic Dis. 2012. PMID: 21894175
-
Nutritional interventions for survivors of childhood cancer.Cochrane Database Syst Rev. 2016 Aug 22;2016(8):CD009678. doi: 10.1002/14651858.CD009678.pub2. Cochrane Database Syst Rev. 2016. PMID: 27545902 Free PMC article.
-
Treatment for osteoporosis in people with beta-thalassaemia.Cochrane Database Syst Rev. 2023 May 9;5(5):CD010429. doi: 10.1002/14651858.CD010429.pub3. Cochrane Database Syst Rev. 2023. PMID: 37159055 Free PMC article.
-
The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.Health Technol Assess. 2007 Feb;11(4):1-134. doi: 10.3310/hta11040. Health Technol Assess. 2007. PMID: 17280622
Cited by
-
Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.Osteoporos Int. 2016 Apr;27(4):1507-1518. doi: 10.1007/s00198-015-3399-0. Epub 2015 Nov 16. Osteoporos Int. 2016. PMID: 26572756 Clinical Trial.
-
Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy.Cancer Manag Res. 2014 Dec 24;7:13-8. doi: 10.2147/CMAR.S74116. eCollection 2015. Cancer Manag Res. 2014. PMID: 25565887 Free PMC article.
-
The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study.Support Care Cancer. 2014 Sep;22(9):2409-15. doi: 10.1007/s00520-014-2183-6. Epub 2014 Apr 3. Support Care Cancer. 2014. PMID: 24696083
-
Androgen regulation of prostate cancer: where are we now?J Endocrinol Invest. 2011 Mar;34(3):232-43. doi: 10.1007/BF03347072. Epub 2011 Feb 4. J Endocrinol Invest. 2011. PMID: 21297383 Review.
-
Risk of Fracture During Androgen Deprivation Therapy Among Patients With Prostate Cancer: A Systematic Review and Meta-Analysis of Cohort Studies.Front Pharmacol. 2021 Aug 6;12:652979. doi: 10.3389/fphar.2021.652979. eCollection 2021. Front Pharmacol. 2021. PMID: 34421586 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical